ESP | ENG

References (31-12-06)

a) VASCULITIS AND ANTI-TNF AGENTS

  1. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666-76. Epub 2005 Apr 4.
  2. Galaria NA, Werth VP, Schumacher HR.  Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000 Aug;27(8):2041-4.  
  3. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003 Oct;30(10):2287-91.
  4. Juan A, Ribas B, Nadal C, Ros I. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept? J Rheumatol. 2005 Oct;32(10):2061; author reply 2061-2. No abstract available.
  5. Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G.  Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol. 2006 Oct;12(5):249-51.
  6. Martinez-Taboada VM, Val-Bernal JF, Pesquera LC, Fernandez-Llanio NE, Esteban JM, Blanco R, Alonso-Bartolome P, Gonzalez-Vela C, Rodriguez-Valverde V. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol. 2006 Jul-Aug;35(4):322-3. No abstract available.
  7. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford). 2002 Jan;41(1):116-7. No abstract available.
  8. McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol. 2003 May-Jun;36(5):411-3.
  9. Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, Braun MM. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004 Oct;31(10):1955-8.
  10. Mor A, Bingham C 3rd, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005 Apr;32(4):740-3.
  11. Orpin SD, Majmudar VB, Soon C, Azam NA, Salim A. Adalimumab causing vasculitis. Br J Dermatol. 2006 May;154(5):998-9. No abstract available.
  12. Richette P, Dieude P, Damiano J, Liote F, Orcel P, Bardin T. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol. 2004 Oct;31(10):2079-81.
  13. Roux CH, Brocq O, Albert C Breuil V, Euller-Ziegler L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine. 2004 Sep;71(5):444-5. No abstract available.
  14. Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006 Dec;73(6):710-3. Epub 2006 Aug 30.
  15. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol. 2004 Jul;31(7):1467. No abstract available.
  16. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol. 2005 Apr;61(4):329-36.
  17. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005 Jul;20(7):1400-6. Epub 2005 Apr 19.
  18. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003 Nov;28(6):604-7. Review.
  19. Tektonidou MG, Serelis J, Skopouli FN. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol. 2007 Feb;26(2):258-60. Epub 2006 Jul 6.
  20. Wendling D, Streit G, Lehuede G, Toussirot E, Aubin A, Petitjean A. Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis. Joint Bone Spine. 2006 Mar;73(2):215-6. Epub 2005 Jul 22. No abstract available.

b) LUPUS AND ANTI-TNF AGENTS

  1. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med. 2002 Oct 1;137(7):625-6. No abstract available.
  2. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005 Feb;11(1):47-9.
  3. Bleumink GS, ter Borg EJ, Ramselaar CG, Ch  Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2001 Nov;40(11):1317-9. No abstract available.
  4. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med. 1999 Oct 19;131(8):634. No abstract available.
  5. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002 Nov;61(11):1031-2. No abstract available.
  6. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003 Apr;48(4):1165-6; author reply 1166. No abstract available.
  7. Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum. 2006 Feb 15;55(1):163-6. Review. No abstract available.
  8. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000 Nov;43(11):2383-90.
  9. Christopher-Stine L, Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol. 2003 Dec;30(12):2725-7. No abstract available.
  10. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004 Jan;126(1):19-31.
  11. Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol. 2006 Jan;33(1):24-30.
  12. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545-51. Epub 2005 Mar 1.
  13. Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity. 2005 Mar;38(2):155-60.
  14. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11(11):753-5.
  15. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666-76. Epub 2005 Apr 4.
  16. High WA, Muldrow ME, Fitzpatrick JE. Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol. 2005 Apr;52(4):E5. No abstract available.
  17. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006 Oct;21(5):946-9.
  18. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May;9(3):176-8.
  19. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet. 2002 Aug 24;360(9333):646. No abstract available.
  20. Mor A, Bingham C 3rd, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005 Apr;32(4):740-3.
  21. Nancey S, Blanvillain E, Parmentier B, Flourie B, Bayet C, Bienvenu J, Fabien N. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis. 2005 Nov;11(11):986-91.
  22. Novak S, Cikes N. Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping:  with systemic lupus erythematosus (SLE) unmasked by infliximab. Clin Exp Rheumatol. 2004 Mar-Apr;22(2):268. No abstract available.
  23. Pallotta P, Cianchini G, Ruffelli M, Puddu P. Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford). 2006 Jan;45(1):116-7. Epub 2005 Nov 30. No abstractavailable.
  24. Pataka A, Tzouvelekis A, Bouros D. Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption. Eur J Intern Med. 2006 Nov;17(7):520. No abstract available.
  25. Perez-Garcia C, Maymo J, Lisbona Perez MP, Almirall Bernabe M, Carbonell Abello J. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab. Rheumatology (Oxford). 2006 Jan;45(1):114-6. Epub 2005 Nov 30. No abstract available.
  26. Richez C, Dumoulin C, Schaeverbeke T.  Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol. 2005 Apr;32(4):760-1.
  27. Roux CH, Brocq O, Albert C Breuil V, Euller-Ziegler L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine. 2004 Sep;71(5):444-5. No abstract available.
  28. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999 Oct;117(4):761-9.
  29. Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003 Nov;35(11):814-7.
  30. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006 Jul;65(7):889-94. Epub 2006 Jan 26.
  31. Schneider SW, Staender S, Schluter B, Luger TA, Bonsmann G. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol. 2006 Jan;142(1):115-6. No abstract available.
  32. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002 Feb 16;359(9306):579-80.
  33. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005 Jul;20(7):1400-6. Epub 2005 Apr 19.
  34. Stratigos AJ, Antoniou C, Stamathioudaki S, Avgerinou G, Tsega A, Katsambas AD.   Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004 Mar;29(2):150-3.
  35. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003 Nov;28(6):604-7. Review.  
  36. van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford). 2006 Oct;45(10):1317-9. Epub 2006 Jul 13.

c) INTERSTITIAL LUNG DISEASE AND ANTI-TNF AGENTS

  1. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol. 2004;33(4):276-7. No abstract available.
  2. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545-51. Epub 2005 Mar 1.
  3. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006 Oct;21(5):946-9.
  4. Courtney PA, Alderdice J, Whitehead EM. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2003 Aug 15;49(4):617; author reply 617-8. No abstract available.
  5. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V.  Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006 Oct 15;55(5):817-20. Review. No abstract available.
  6. Hennum J, Nace J, Shammash E, Gertner E. Infliximab-associated pneumonitis in rheumatoid arthritis. J Rheumatol. 2006 Sep;33(9):1917-8. No abstract available.
  7. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2002 Dec 15;47(6):670-1. No abstract available.
  8. Martin Carrasco C, Hortal Reina B, Fernandez Vazquez E. [Pulmonary infiltrates after initiation of treatment with infliximab for adult Still's disease] Arch Bronconeumol. 2005 Jun;41(6):355. Spanish. No abstract available.
  9. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006 Dec 15;55(6):978-81. No abstract available.
  10. Ostor AJ, Chilvers ER, Somerville MF, Lim AY, Lane SE, Crisp AJ, Scott DG. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006 Mar;33(3):622-8.
  11. Panagi S, Palka W, Korelitz BI, Taskin M, Lessnau KD. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis. 2004 May;10(3):274-7.
  12. Pataka A, Tzouvelekis A, Bouros D. Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption. Eur J Intern Med. 2006 Nov;17(7):520. No abstract available.
  13. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 2005 Aug 15;53(4):618-20. No abstract available.
  14. Quintos-Macasa AM, Quinet R. Enbrel-induced interstitial lung disease. South Med J. 2006 Jul;99(7):783-4. No abstract available.
  15. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 2006 Feb 15;55(1):157-9. No abstract available.
  16. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006 Jun;33(6):1189-93. Epub 2006 Apr 15.
  17. Weatherhead M, Masson S, Bourke SJ, Gunn MC, Burns GP. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis. 2006 May;12(5):427-8. No abstract available.

 

d) OTHER AUTOIMMUNE DISEASES AND ANTI-TNF AGENTS

  1. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford). 2003 Dec;42(12):1566-8. No abstract available.
  2. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666-76. Epub 2005 Apr 4.
  3. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006 Jul;65(7):889-94. Epub 2006 Jan 26.

Back to eaBIOGEAS